Research and development, technologies and products
At Crucell we bring meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge. In the following pages we highlight Crucell’s key innovations in the field of research and development, our cutting-edge technologies and robust product portfolio.
- €100.0 mln
Invested in research and
development in 2010. - 105+ mln
Doses distributed in 2010.
- 100 countries
Crucell vaccines were distributed in more
than 100 countries in 2010.
| Development stage | Discovery/ Pre-clinical | Phase I | Phase II | Phase III | Marketed | Description |
|---|---|---|---|---|---|---|
| Marketed products: | ||||||
| Quinvaxem® |  |
 |
 |
 |
 |
Fully liquid vaccine for protection against five childhood diseases. |
| Hepavax-Gene® | |
|
|
|
|
Recombinant hepatitis B vaccine. |
| Epaxal® Junior | |
|
|
|
|
Low dosage aluminum-free hepatitis A vaccine (0.25ml). |
| MoRu-Viraten® | |
|
|
|
|
Vaccine for protection against measles and rubella. |
| Epaxal® | |
|
|
|
|
Aluminum-free hepatitis A vaccine. |
| Vivotif® | |
|
|
|
|
Oral typhoid vaccine. |
| Dukoral® | |
|
|
|
|
Only internationally licensed oral vaccine against cholera. |
| Inflexal® V | |
|
|
|
|
Virosomal adjuvanted influenza vaccine. |
| Vaccines in development: | ||||||
| Flavimun® |  |
 |
 |
 |
Yellow fever vaccine. | |
| Tuberculosis | |
|
|
Recombinant AdVac®-based tuberculosis vaccine.1 | ||
| Malaria | |
|
Recombinant AdVac®-based malaria vaccine.2 | |||
| Ebola and Marburg | |
|
Recombinant AdVac®-based Ebola and Marburg vaccine.2 | |||
| HIV | |
|
Recombinant AdVac®-based vaccine.3 | |||
| Cell-based Influenza | |
|
Seasonal influenza vaccine produced on PER.C6.® | |||
| Universal Influenza | |
Universal influenza vaccine produced on PER.C6.® | ||||
| HPV | |
Recombinant AdVac®-based HPV vaccine.4 | ||||
| RSV | |
Recombinant AdVac®-based RSV vaccine.5 | ||||
| Human monoclonal antibodies in development: | ||||||
| Rabies antibody combination |  |
 |
 |
Mix of two monoclonal antibodies for post-exposure treatment of rabies.6 | ||
| Influenza antibodies | |
Antibodies neutralizing a wide range of influenza subtypes, including H5 and H1. | ||||
| Hepatitis C antibody combination | |
Neutralizing monoclonal antibody combination across all genotypes tested. | ||||
- 1
- Partnered with Aeras.
- 2
- Partnered with NIH/NIAID, GSK.
- 3
- Partnered with Harvard.
- 4
- Human papilloma virus (HPV), partnered with Johnson & Johnson.
- 5
- Respiratory syncytial virus (RSV), partnered with Johnson & Johnson.
- 6
- Partnered with sanofi pasteur.